SPECIAL ISSUE: Frontiers of Health Policy Research

Health Economics, Policy and Law
Volume 14 – Special Issue 2 – April 2019
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
SPECIAL ISSUE: Frontiers of Health Policy Research
If the enhancement of human freedom is both the main object and the primary means to development (Sen, 1999), then good individual and population health are both ends and means to development and freedom in all countries, regardless of their current ranking on the Human Development Index or other indexes on wealth, prosperity and well-being…
This special issue on the ‘frontiers in health policy research’ focuses attention on three distinct areas of inquiry. One set of papers analyses efforts to improve the quality of care and increase the value of care that health systems purchase. A second set of articles focuses on issues of health behaviour and social determinants of health. Finally, the third set of articles presents differing views on how to predict the adequacy of supply of medical professionals. The range of these articles illustrates, not only the exciting breadth of health policy research, but the degree to which scholars within this field are addressing issues of high importance to policy makers around the world. We think it is fair to claim that all of the articles address issues that are on the ‘frontier’ of health policy in the sense that they attempt to provide answers to questions that policy makers around the world are currently grappling with…

 

Realizing their potential to become learning organizations to foster health system resilience: opportunities and challenges for health ministries in low- and middle-income countries

Health Policy and Planning
Volume 33, Issue 10, 1 December 2018
https://academic.oup.com/heapol/issue/33/10

Original Articles
Realizing their potential to become learning organizations to foster health system resilience: opportunities and challenges for health ministries in low- and middle-income countries
Joseph F Naimoli; Sweta Saxena
Health Policy and Planning, Volume 33, Issue 10, 1 December 2018, Pages 1083–1095, https://doi.org/10.1093/heapol/czy100

 

Communication and community engagement in humanitarian response

Humanitarian Exchange Magazine
Number 74, February 2019
https://odihpn.org/magazine/communication-community-engagement-humanitarian-response/
Communication and community engagement in humanitarian response
This edition of Humanitarian Exchange, co-edited with Charles-Antoine Hofmann from the UN Children’s Fund (UNICEF), focuses on communication and community engagement. Despite promising progress, coherent and coordinated information is still not provided systematically to affected communities, and humanitarian responses take insufficient account of the views and feedback of affected people. In 2017, UNICEF, the International Federation of Red Cross and Red Crescent Societies (IFRC), the UN Office for the Coordination of Humanitarian Affairs (OCHA) and other partners came together under the auspices of the Communicating with Disaster Affected Communities (CDAC) Network to establish the Communication and Community Engagement (CCE) initiative, which aims to organise a collective service for communications and community engagement. The articles in this edition take stock of efforts to implement this initiative.

Drawing on lessons from 23 Peer 2 Peer Support missions, Alice Chatelet and Meg Sattler look at what’s needed to integrate CCE into the humanitarian architecture. Viviane Lucia Fluck and Dustin Barter discuss the institutional and practical barriers to implementing community feedback mechanisms. Bronwyn Russel analyses the performance of the Nepal inter-agency common feedback project; Justus Olielo and Charles-Antoine Hofmann outline the challenges of establishing common services in Yemen; and Gil Francis Arevalo reports on community engagement in preparedness and response in the Philippines. Ian McClelland and Frances Hill discuss emerging findings from a strategic partnership in the Philippines between the Humanitarian Innovation Fund and the Asian Disaster Reduction and Response Network.

Charlotte Lancaster describes how call centres in Afghanistan and Iraq are enhancing two-way communication with crisis-affected people. Mia Marzotto from Translators without Borders reflects on the importance of language and translation in communication and community engagement, and Ombretta Baggio and colleagues report on efforts to bring community perspectives into decision-making during an Ebola outbreak in the Democratic Republic of Congo. Ayo Degett highlights emerging findings from a Danish Refugee Council project on participation in humanitarian settings, and Jeff Carmel and Nick van Praag report on the Listen Learn Act (LLA) project. Geneviève Cyvoct and Alexandra T. Warner write on an innovative common platform to track the views of affected people in Chad. The edition ends with an article by Stewart Davies on collective accountability in the response to the Central Sulawesi earthquake.

 

Epidemiology and management of hepatitis C virus infections in immigrant populations

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 16 Mar 2019]

Scoping Review
|   15 March 2019
Epidemiology and management of hepatitis C virus infections in immigrant populations
At present, there is a continuous flow of immigrants from the south of the world to north-western countries. Often immigrants originate from areas of high-prevalence of viral hepatitis and pose a challenge to the healthcare systems of the host nations. Aims of this study is to evaluate the prevalence and virological and clinical characteristics of hepatitis C virus (HCV) infection in immigrants and the strategies to identify and take care of the immigrants infected with HCV.
Authors: Nicola Coppola, Loredana Alessio, Lorenzo Onorato, Caterina Sagnelli, Margherita Macera, Evangelista Sagnelli and Mariantonietta Pisaturo

Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan

International Journal of Infectious Diseases
March 2019 Volume 80, p1-152
https://www.ijidonline.com/issue/S1201-9712(19)X0002-8

Original Reports
Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan
Atif Riaz, Syed Mohiuddin, Sara Husain, Mohammad Tahir Yousafzai, Muhammad Sajid, Furqan Kabir, Najeeb ur Rehman, Waseem Mirza, Basit Salam, Naila Nadeem, Khatidja Pardhan, Khalid Mehmood A. Khan, Syed Jamal Raza, Fehmina Arif, Khalid Iqbal, Hassan Khalid Zuberi, Cynthia G. Whitney, Saad B. Omer, Anita K.M. Zaidi, Asad Ali, Pakistan Pneumococcal Vaccine Study Group
p28–33
Published online: December 18, 2018

Supporting Adolescent Sexual and Reproductive Health Rights Through Innovative Research Approaches

Journal of Adolescent Health
March 2019 Volume 64, Issue 3, p283-418
https://www.jahonline.org/issue/S1054-139X(18)X0005-6

Editorials
Supporting Adolescent Sexual and Reproductive Health Rights Through Innovative Research Approaches
Devon J. Hensel
p288–289
Published in issue: March 2019
International health care governing bodies define the ability to achieve and maintain sexual and reproductive health (SRH) as a fundamental human right [1, 2, 3]. This rights-based paradigm places at its core—for individuals of all ages but especially for adolescents and young adults [4]—the ability to access accurate SRH-focused information and education, as well as to receive developmentally appropriate, SRH-focused preventative counseling and clinical care [5, 6]. A rights-based framework also both recognizes that many young people face multiplicative barriers to adequate care based on social or economic factors (e.g., gender-based, race-based, or sexual identity–based discrimination, poverty, residential instability, migration, military conflict) [7, 8, 9]. As health professionals who operate in a political environment that continually threatens the well-being of young people, we are well aware that both marginalized and disenfranchised youth experience the greatest problems every day to obtaining SRH services [10] and suffer the highest cumulative burden of downstream consequences in adulthood when SRH care needs are not met [11, 12]. Now more than ever, we must double down on our efforts to be front-line defenders of adolescent and young adult SRH rights. Such active stewardship requires us to pay careful attention—as clinicians, as educators and as researchers—and continually commit ourselves to engaging in evidence-based approaches that highlight how and when interlocking sources of disadvantage create unique vulnerabilities in young people’s access to SRH [13].

One way in which we expand our evidence base in ways consistent with a sexual rights perspective is choosing data analysis techniques that are deliberately intended to model the overlap in factors known to create obstacles to SRH [14, 15]. In this issue of the Journal of Adolescent Health, Hill et al. [16] provide an important application of these principles, using latent class analysis (LCA) to identify how syndemic patterns—or clusters of co-occurring behavioral, socioeconomic, and environmental factors [17, 18, 19]—interact to increase vulnerability to sexually transmitted infection (STI) among young adults in the United States…

 

Research Ethics Committees’ Oversight of Biomedical Research in South Africa: A Thematic Analysis of Ethical Issues Raised During Ethics Review of Non-Expedited Protocols

Journal of Empirical Research on Human Research Ethics
Volume 14 Issue 2, April 2019
http://journals.sagepub.com/toc/jre/current

Functioning and Outcomes of IRBs/RECs
Research Ethics Committees’ Oversight of Biomedical Research in South Africa: A Thematic Analysis of Ethical Issues Raised During Ethics Review of Non-Expedited Protocols
Blessing Silaigwana, Douglas Wassenaar
First Published January 24, 2019; pp. 107–116

Inclusion of Marginalized Groups and Communities in Global Health Research Priority-Setting

Journal of Empirical Research on Human Research Ethics
Volume 14 Issue 2, April 2019
http://journals.sagepub.com/toc/jre/current

Ethical Issues in Research with Marginalized Groups
Inclusion of Marginalized Groups and Communities in Global Health Research Priority-Setting
Bridget Pratt
First Published March 13, 2019; pp. 169–181
Abstract
Community engagement is gaining prominence in global health research. But community members, especially those from groups and communities that are considered disadvantaged and marginalized, rarely have a say in the agendas and priorities of the research projects that aim to help them. This article explores how to achieve their inclusion in priority-setting for global health research projects. A total of 29 in-depth interviews and one focus group were undertaken with researchers, research ethicists, community engagement practitioners, and community-based organization staff. Thematic analysis identified two core dimensions of inclusion—representation and voice—and what is necessary to realize them with marginalized groups and communities in global health research priority-setting. A set of ethical considerations is proposed to assist researchers and their partners design more inclusive priority-setting processes.

WHO reform continues to confuse

The Lancet
Mar 16, 2019, Volume 393  Number 10176  p1071-1176
https://www.thelancet.com/journals/lancet/issue/current

Editorial
WHO reform continues to confuse
The Lancet
The content of a reform for WHO came as somewhat of a surprise to many in the global health community. After Dr Tedros Adhanom Ghebreyesus, in his inaugural speech, said “I do not believe in perpetual reform and I think WHO staff are reformed out”, WHO’s Director-General unveiled the result of a 20-month-long consultation for reform. Aimed to be “the most wide-ranging reforms in the organisation’s history”, according to the accompanying press release, this reform is a substantial top-heavy redesign of the internal structure of the WHO Secretariat.

The reform was announced in a speech to staff on March 6. In the speech, Dr Tedros and WHO’s six Regional Directors (RDs) took turns to speak about the reform. Historically, WHO has often been referred to as not one but seven WHOs. That RDs are locally elected, thus retaining significant autonomy over their regional and country priorities, has often been said adds fragmentation and compartmentalisation to the organisation. By calling on the RDs to be part and parcel of the announcement, Dr Tedros reiterated the message of one WHO.

The reform is aimed to “address gaps in [universal health coverage], health emergencies, and healthier populations”, guided by Dr Tedros’s Triple Billion targets. From March 15, there will be only one Deputy Director-General (DDG) reporting to Dr Tedros—Hungarian Zsuzsanna Jakab, formerly RD of WHO Europe—down from three DDGs.

The Programmes, which formerly reported directly to the Director-General, will now be led by Assistant Director-Generals (ADGs) reporting to the DDG (with the exception of the UHC and Life Course Programme led by Australian Executive Director Peter Salama who will be reporting jointly to the DDG and Dr Tedros). The new organisation of programmes reads somewhat confusingly. Where integration of the communicable and non-communicable diseases into one programme could create opportunities for more holistic approaches to disease, it is unclear why it was combined with UHC, or why antimicrobial disease was separated into a programme of its own. Importantly, the maternal, child, and adolescent health cluster, which one would expect to fall under the new UHC and Life Course Programme, seems to be missing from the organogram circulated to staff in an internal memo after the announcement, although The Lancet was told by WHO that it has not yet been finalised. This is all the more surprising given that maternal and child health was one of Dr Tedros’s five campaign priorities.

Indian paediatrician and former DDG Soumya Swaminathan was appointed to a new role, Chief Scientist, to head a division that is tasked with supporting, developing, and maintaining the excellence of the norms and standards of WHO. Notably, a new Division of Data, Analytics, and Delivery for Impact, headed by the American ADG Samira Asma, will not report to the Chief Scientist, but to Dr Tedros.

The perennial issue of WHO’s funding structure was also brought to the fore. Although WHO depends on reliable contributions from its member states, most of its funding comes from voluntary contributions, which can be highly variable and heavily earmarked for the donors’ interests. In his speech, Dr Tedros made it clear that he will be attempting a major reform of this system. The decision to take fundraising out of the programmes into a centralised fundraising department is “part of a much bigger shift in the way [WHO] generates resources, to diversify our funding base and make us less reliant on a handful of major donors”, he said. A new resource mobilisation strategy, the establishment of a so-called WHO Foundation, to develop innovative financing mechanisms, and a new yearly WHO Partners Forum were announced. This all points to the possibility that WHO’s strategy for funding going forward might be the establishment of a centralised pot of money for voluntary contributions. However, whether the member states and major donors, such as the US Government and the Bill & Melinda Gates Foundation, would be compliant with such a mechanism is uncertain. A week after the speech was given, experts contacted by The Lancet communicated their continuing confusion about this reform. As we go to press, a marked lack of communication surrounds the announcement and a detailed report explaining the specifics of what the reform means for programmes, oversight, funding, and staffing is not yet available. In the meantime, the global health community is still holding its breath, waiting to see whether this reform represents a transformational shift in vision for WHO or simply a shuffling of clusters and staff.

Progress in adolescent health and wellbeing: tracking 12 headline indicators for 195 countries and territories, 1990–2016

The Lancet
Mar 16, 2019, Volume 393  Number 10176  p1071-1176
https://www.thelancet.com/journals/lancet/issue/current

Articles
Progress in adolescent health and wellbeing: tracking 12 headline indicators for 195 countries and territories, 1990–2016
Peter S Azzopardi,Stephen J C Hearps,Kate L Francis, Elissa C Kennedy, Ali H Mokdad, Nicholas J Kassebaum, Stephen Lim, Caleb M S Irvine, Theo Vos, Alex D Brown, Surabhi Dogra,  Stuart A Kinner, Natasha S Kaoma, Mariam Naguib, Nicola J Reavley, Jennifer Requejo, John S Santelli,
Susan M Sawyer, Vegard Skirbekk, Marleen Temmerman, Jordan Tewhaiti-Smith, Joseph L Ward, Russell M Viner, George C Patton
Open Access

Adopt a moratorium on heritable genome editing

Nature 
Volume 567 Issue 7747, 14 March 2019
http://www.nature.com/nature/current_issue.html

Comment | 13 March 2019
Adopt a moratorium on heritable genome editing
Eric Lander, Françoise Baylis, Feng Zhang, Emmanuelle Charpentier, Paul Berg and specialists from seven countries call for an international governance framework.
Eric S. Lander, Françoise Baylis[…] & Ernst-Ludwig Winnacker

Lump sum agreements may allow universal access to drugs

PharmacoEconomics & Outcomes News
Volume 823, Issue 1, March 2019
https://link.springer.com/journal/40274/823/1

Clinical study
Lump sum agreements may allow universal access to drugs
Moon S, et al.
Australia’s agreement to spend about 1 billion Australian dollars (US $766 million) over 5 years in exchange for an unlimited volume of hepatitis C drugs suggests that, under certain conditions, innovative approaches to payment can remove price as a barrier to access.

 

Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 16 Mar 2019)

Research Article
Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera
Justin Im, Md. Taufiqul Islam, Faisal Ahmmed, Deok Ryun Kim, Yun Chon, K Zaman, Ashraful Islam Khan, Mohammad Ali, Florian Marks, Firdausi Qadri, John D. Clemens
Research Article | published 14 Mar 2019 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0007179
Abstract
Analyses of stool from patients with acute watery diarrhea (AWD) using sensitive molecular diagnostics have challenged whether fecal microbiological cultures have acceptably high sensitivity for cholera diagnosis. If true, these findings imply that current estimates of the global burden of cholera, which rely largely on culture-confirmation, may be underestimates. We conducted a vaccine probe study to evaluate this possibility, assessing whether an effective killed oral cholera vaccine (OCV) tested in a field trial in a cholera-endemic population conferred protection against cholera culture-negative AWD, with the assumption that if cultures are indeed insensitive, OCV protection in such cases should be detectable. We re-analysed the data of a Phase III individually-randomized placebo-controlled efficacy trial of killed OCVs conducted in Matlab, Bangladesh in 1985. We calculated the protective efficacy (PE) of a killed whole cell-only (WC-only) OCV against first-episodes of cholera culture-negative AWD during two years of post-dosing follow-up. In secondary analyses, we evaluated PE against cholera culture-negative AWD by age at vaccination, season of onset, and disease severity. In this trial 50,770 people received at least 2 complete doses of either WC-only OCV or placebo, and 791 first episodes of AWD were reported during the follow-up period, of which 365 were culture-positive for Vibrio cholerae O1. Of the 426 culture-negative AWD episodes, 215 occurred in the WC group and 211 occurred in the placebo group (adjusted PE = -1.7%; 95%CI -23.0 to 13.9%, p = 0.859). No measurable PE of OCV was observed against all or severe cholera culture-negative AWD when measured overall or by age and season subgroups. In this OCV probe study we detected no vaccine protection against AWD episodes for which fecal cultures were negative for Vibrio cholera O1. Results from this setting suggest that fecal cultures from patients with AWD were highly sensitive for cholera episodes that were etiologically attributable to this pathogen. Similar analyses of other OCV randomized controlled trials are recommended to corroborate these findings.
Author summary
Conventional microbiological culture has remained a relatively uncontested ‘gold standard’ for the diagnosis of cholera; however, emerging methods, including sensitive molecular tests, challenge the current paradigm. One pivotal article demonstrated that culture failed to detect cholera in one-third of the cholera-positive stool specimens confirmed by other methods. This finding underscored the absence of a reliable reference test, further complicated by newer tests outperforming the gold standard, leaving no suitable comparator. In this study, we used oral cholera vaccine as a probe to investigate the reliability of conventional culture as a diagnostic for cholera by measuring the effectiveness of the vaccine against cholera culture-negative acute watery diarrhea. We did not find any evidence of protection, implying that the culture diagnostics used were reliable. The dynamics of cholera transmission require a rapid response, and ascertaining the best rapid diagnostic test for early detection of outbreaks will maximize the effectiveness of chronically limited resources in high risk regions. As techniques advance, well-designed studies should be implemented to systematically evaluate their merit against established methods, and improved diagnostics, including rapid diagnostics and microbiological culture, should be implemented into cholera control programs to reduce cholera transmission by creating a better trigger for outbreak response.

 

The genomic landscape of pediatric cancers: Implications for diagnosis and treatment

Science         
15 March 2019   Vol 363, Issue 6432
http://www.sciencemag.org/current.dtl
Special Issue – Pediatric Cancer

Reviews
The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
By E. Alejandro Sweet-Cordero, Jaclyn A. Biegel
Science15 Mar 2019 : 1170-1175 Full Access
Abstract
The past decade has witnessed a major increase in our understanding of the genetic underpinnings of childhood cancer. Genomic sequencing studies have highlighted key differences between pediatric and adult cancers. Whereas many adult cancers are characterized by a high number of somatic mutations, pediatric cancers typically have few somatic mutations but a higher prevalence of germline alterations in cancer predisposition genes. Also noteworthy is the remarkable heterogeneity in the types of genetic alterations that likely drive the growth of pediatric cancers, including copy number alterations, gene fusions, enhancer hijacking events, and chromoplexy. Because most studies have genetically profiled pediatric cancers only at diagnosis, the mechanisms underlying tumor progression, therapy resistance, and metastasis remain poorly understood. We discuss evidence that points to a need for more integrative approaches aimed at identifying driver events in pediatric cancers at both diagnosis and relapse. We also provide an overview of key aspects of germline predisposition for cancer in this age group.

 

Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review

Vaccine
Volume 37, Issue 13 Pages 1721-1904 (22 March 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/13

Review article  Open access
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review
Emma J. Walker, Noni E. MacDonald, Nehal Islam, Nicole Le Saux, … Deshayne B. Fell
Pages 1725-1735

Hospital contacts and diagnoses five years prior to HPV vaccination among females referred for suspected adverse vaccine effects: A Danish nationwide case-control study

Vaccine
Volume 37, Issue 13 Pages 1721-1904 (22 March 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/13

Research article  Abstract only
Hospital contacts and diagnoses five years prior to HPV vaccination among females referred for suspected adverse vaccine effects: A Danish nationwide case-control study
Lene Wulff Krogsgaard, Bodil Hammer Bech, Oleguer Plana-Ripoll, Reimar Wernich Thomsen, Dorte Rytter
Pages 1763-1768

Vaccine hesitancy and Web 2.0: Exploring how attitudes and beliefs about influenza vaccination are exchanged in online threaded user comments

Vaccine
Volume 37, Issue 13 Pages 1721-1904 (22 March 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/13

Research article  Abstract only
Vaccine hesitancy and Web 2.0: Exploring how attitudes and beliefs about influenza vaccination are exchanged in online threaded user comments
Samantha B. Meyer, Richard Violette, Reenika Aggarwal, Michelle Simeoni, … Nancy Waite
Pages 1769-1774

HPV vaccination and sexual health in France: Empowering girls to decide

Vaccine
Volume 37, Issue 13 Pages 1721-1904 (22 March 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/13

Research article  Abstract only
HPV vaccination and sexual health in France: Empowering girls to decide
Hervé Lefevre, Stéphanie Samain, Nour Ibrahim, Christine Fourmaux, … Jonathan Lachal
Pages 1792-1798
Conclusions
Teenage girls know little about this vaccine and are more sensitive to the emotional discourse that surrounds it than to rational knowledge about it. The requirement for parental authorization for this vaccine reinforces the girls’ lack of investment. Vaccination programs should integrate the HPV vaccine more thoroughly into general prevention concerning sexual health and should send a strong signal by offering minors anonymous vaccination free of charge, as is already the case in France for requests for contraception, the morning-after pill, elective abortion, and screening and treatment of sexually transmitted infections.

Redefining vaccination coverage and timeliness measures using electronic immunization registry data in low- and middle-income countries

Vaccine
Volume 37, Issue 13 Pages 1721-1904 (22 March 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/13

Research article  Open access
Redefining vaccination coverage and timeliness measures using electronic immunization registry data in low- and middle-income countries
Samantha B. Dolan, Emily Carnahan, Jessica C. Shearer, Emily N. Beylerian, … Tove K. Ryman
Pages 1859-1867

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 
 

The Associated Press
https://apnews.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 16 Mar 2019
[No new, unique, relevant content]

BBC
http://www.bbc.co.uk/
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
The Economist
http://www.economist.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 16 Mar 2019
Mar 13, 2019
AMA Enlists Social Media Giants To Stop Spread Of Anti-Vaccine Misinformation
The American Medical Association urged big social media and tech companies including Amazon, Facebook and Google to stop vaccine misinformation on their platforms.
By Bruce Japsen Contributor
[See Milestones above for full letter]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 16 Mar 2019
Vaccines and immunisation
How to put the dangerous anti-vaxx panic in perspective: zoom out
‘Vaccine hesitancy’ persists despite the body of evidence showing that there is no link between the MMR vaccine and autism
Fri 15 Mar 2019 01.00 EDT
 
 
New Yorker
http://www.newyorker.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 16 Mar 2019
Travel
With Measles Outbreaks on the Rise, a Concern Over the Connection to Air Travel
A record 81 U.S. flights were investigated in 2018 for carrying at least one person contagious with the disease, which has had a large number of outbreaks this year.
March 14

New York
Parents Wanted Their Unvaccinated Children in School, but a Judge Said No.
Amid a measles outbreak in New York, a federal judge denied a request by 28 parents for an order to let their unvaccinated children return to their private school.
March 13

Europe
Vaccine Law Returns to Force in Italy, Barring 300 Children From Kindergarten
A stricter law on vaccination returned to force in Italy. Dozens of other children across Italy were also likely to be affected
March 13

Americas
Mumps, Other Outbreaks Force U.S. Detention Centers to Quarantine Over 2,000 Migrants
Christian Mejia thought he had a shot at getting out of immigration detention in rural Louisiana after he found a lawyer to help him seek asylum.
March 11

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 16 Mar 2019
[No new, unique, relevant content]
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 16 Mar 2019
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al

 

Brookings
http://www.brookings.edu/
Accessed 16 Mar 2019
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center
[No new relevant content]

CSIS
https://www.csis.org/
Accessed 16 Mar 2019
Podcast Episode
The Anti-Vaxxer Movement and its Implications on Public Health
March 12, 2019 | By J. Stephen Morrison

Council on Foreign Relations
http://www.cfr.org/
Accessed 16 Mar 2019
March 14, 2019
Health
Democracy Matters in Global Health
Panelists will discuss the links between democratic governance and global health.
Event by Joseph L. Dieleman, Thomas Carothers, Simon Wigley, and V. Kate Somvongsiri

March 12, 2019
Pharmaceuticals and Vaccines
Measles and the Threat of the Anti-vaccination Movement
Measles cases have spiked as a growing number of anti-vaxxers, opting out of immunizations for their kids, threaten decades of progress toward eliminating the disease.
by Claire Felter

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 16 Mar 2019
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 09 March 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_9 Mar 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Facebook – Combatting Vaccine Misinformation

Milestones :: Perspectives

Facebook – Combatting Vaccine Misinformation
March 7, 2019
By Monika Bickert, VP, Global Policy Management

We are working to tackle vaccine misinformation on Facebook by reducing its distribution and providing people with authoritative information on the topic. We are starting by taking a series of steps:

:: We will reduce the ranking of groups and Pages that spread misinformation about vaccinations in News Feed and Search. These groups and Pages will not be included in recommendations or in predictions when you type into Search.

:: When we find ads that include misinformation about vaccinations, we will reject them. We also removed related targeting options, like “vaccine controversies.” For ad accounts that continue to violate our policies, we may take further action, such as disabling the ad account.

:: We won’t show or recommend content that contains misinformation about vaccinations on Instagram Explore or hashtag pages.

:: We are exploring ways to share educational information about vaccines when people come across misinformation on this topic.

How This Will Work

Leading global health organizations, such as the World Health Organization and the US Centers for Disease Control and Prevention, have publicly identified verifiable vaccine hoaxes. If these vaccine hoaxes appear on Facebook, we will take action against them.

For example, if a group or Page admin posts this vaccine misinformation, we will exclude the entire group or Page from recommendations, reduce these groups and Pages’ distribution in News Feed and Search, and reject ads with this misinformation.

We also believe in providing people with additional context so they can decide whether to read, share, or engage in conversations about information they see on Facebook. We are exploring ways to give people more accurate information from expert organizations about vaccines at the top of results for related searches, on Pages discussing the topic, and on invitations to join groups about the topic. We will have an update on this soon.

We are fully committed to the safety of our community and will continue to expand on this work.

NAS, NAE, and NAM Presidents Highlight Facts on Vaccine Safety in Light of Measles Outbreaks

Milestones :: Perspectives

NAS, NAE, and NAM Presidents Highlight Facts on Vaccine Safety in Light of Measles Outbreaks
March 8, 2019
The current measles outbreaks in the United States and elsewhere are being fueled by misinformation about the safety of vaccines.  To help counter such misinformation, we created a website that provides clear, concise, and evidence-based answers to questions about vaccine safety and other commonly asked questions about health and science as identified through our partnership with Google.

The evidence base includes a number of our studies examining vaccine access, safety, scheduling, and possible side effects.  Our work has validated that the science is clear – vaccines are extremely safe.

Given our shared congressional mandate to advise the nation, we are compelled to draw attention to these facts in order to inform better decision-making at a time when it is urgently needed to protect the health of communities in our country and around the world.  Furthermore, we call on our professional colleagues everywhere to share these facts as widely as possible.  Please consider sharing our social media posts on your own accounts through the links below.

Marcia McNutt
President, National Academy of Sciences
C. D. Mote, Jr.
President, National Academy of Engineering
Victor J. Dzau
President, National Academy of Medicine

 

WHO unveils sweeping reforms in drive towards “triple billion” targets

Milestones :: Perspectives

WHO unveils sweeping reforms in drive towards “triple billion” targets
6 March 2019 News Release Geneva
WHO today announced the most wide-ranging reforms in the Organization’s history to modernize and strengthen the institution to play its role more effectively and efficiently as the world’s leading authority on public health.

The changes are designed to support countries in achieving the ambitious “triple billion” targets that are at the heart of WHO’s strategic plan for the next five years: one billion more people benefitting from universal health coverage (UHC); one billion more people better protected from health emergencies; and one billion more people enjoying better health and well-being.

These changes include:
:: Aligning WHO’s processes and structures with the “triple billion” targets and the Sustainable Development Goals by adopting a new structure and operating model to align the work of headquarters, regional offices and country offices, and eliminate duplication and fragmentation.

:: Reinforcing WHO’s normative, standard-setting work, supported by a new Division of the Chief Scientist and improved career opportunities for scientists.

:: Harnessing the power of digital health and innovation by supporting countries to assess, integrate, regulate and maximize the opportunities of digital technologies and artificial intelligence, supported by a new Department of Digital Health.

:: Making WHO relevant in all countries by overhauling the Organization’s capabilities to engage in strategic policy dialogue. This work will be supported by a new Division of Data, Analytics and Delivery to significantly enhance the collection, storage, analysis and usage of data to drive policy change in countries. This division will also track and strengthen the delivery of WHO’s work by monitoring progress towards the “triple billion targets” and identifying roadblocks and solutions.

:: Investing in a dynamic and diverse workforce through new initiatives including the WHO Academy, a proposed state-of-the-art school to provide new learning opportunities for staff and public health professionals globally. Other measures include a streamlined recruitment process to cut hiring time in half,  management trainings, new opportunities for national professional officers, and previously-announced improvements in conditions for interns.

:: Strengthening WHO’s work to support countries in preventing and mitigating the impact of outbreaks and other health crises by creating a new Division of Emergency Preparedness, as a complement to WHO’s existing work on emergency response.

:: Reinforcing a corporate approach to resource mobilization aligned with strategic objectives and driving new fundraising initiatives to diversify WHO’s funding base, reduce its reliance on a small number of large donors and strengthen its long-term financial stability.

“The changes we are announcing today are about so much more than new structures, they’re about changing the DNA of the organization to deliver a measurable impact in the lives of the people we serve,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Our vision remains the same as it was when we were founded in 1948: the highest attainable standard of health for all people. But the world has changed, which is why we have articulated a new mission statement for what the world needs us to do now: to promote health, keep the world safe and serve the vulnerable.”

The new measures were developed following an extensive period of consultation with staff, and were developed jointly by WHO’s Global Policy Group, which consists of the Director-General and each of the organization’s six regional directors: Dr Matshidiso Moeti (Regional Director for Africa), Dr Carissa Etienne (Regional Director for the Americas), Dr Poonam Khetrapal Singh (Regional Director for South-East Asia), Dr Zsuzsanna Jakab (Regional Director for Europe), Dr Ahmed Al-Mandhari (Regional Director for the Eastern Mediterranean) and Dr Takeshi Kasai (Regional Director for the Western Pacific).

WHO’s new corporate structure is based on four pillars which will be mirrored throughout the organization.

The Programmes pillar will support WHO’s work on universal health coverage and healthier populations. The Emergencies pillar will be responsible for WHO’s critical health security responsibilities, both in responding to health crises and helping countries prepare for them. The External Relations and Governance pillar will centralize and harmonize WHO’s work on resource mobilization, communications. The Business Operations pillar will likewise ensure more professionalized delivery of key corporate functions such as budgeting, finance, human resources and supply chain.

The four pillars will be supplemented by the Division of the Chief Scientist at WHO Headquarters in Geneva to strengthen WHO’s core scientific work and ensure the quality and consistency of WHO’s norms and standards.

Underpinning the new structure, 11 business processes have been redesigned, including planning, resource mobilization, external and internal communications, recruitment, supply chain, performance management, norms and standards, research, data and technical cooperation.

The Global Policy Group stressed the role of working with partners. Dr Tedros said WHO must develop a new mindset to seek out and build partnerships that harness the combined strength of the global health community – both in the public and private sectors. One example of this is a new Global Action Plan for Healthy Lives and Well-Being for All, under which 12 partner organizations are working together to achieve health-related Sustainable Development Goals.

::::::
::::::

exchange of letters between MSF and CEPI around the critical issue of equitable access to vaccines

Milestones :: Perspectives

Editor’s Note:

We provide the full text of an exchange of letters between MSF and CEPI around the critical issue of equitable access to vaccines and how this is achieved and assured in the development context.

 

Open letter to CEPI Board Members: Revise CEPI’s access policy
MSF Letter  05 March 2019
Ahead of CEPI’s Board Meeting in Tokyo on 7–8 March 2019, MSF sent a letter to the organisation’s Board Members to express our concern and disappointment in CEPI’s revised Equitable Access Policy.

The Coalition for Epidemic Preparedness Innovations (CEPI) was launched in 2017 to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics.

MSF engaged with CEPI as they developed and revised their Equitable Access Policy. CEPI’s original access policy contained clear commitments on pricing and the treatment of intellectual property, reflecting CEPI’s promise of public-interest R&D. The revised policy, adopted in December 2018, is a startling reversal. It does not ensure CEPI-funded vaccines will be affordable for people who need them most and does not protect the collective public and philanthropic investment that underpin the initiative.

Ahead of their meeting in Japan on 7–8 March 2019, we wrote a letter to CEPI’s Board to express our concern and disappointment in the revised Equitable Access Policy and to urge them to take swift action to develop and approve a new policy with bold commitments to affordable access and transparency for all CEPI-funded vaccines.

Letter

5 March 2019
CEPI
Oslo, Norway
Re: CEPI Equitable Access Policy
CC:
Cherry Gagandeep Kang, David Reddy, Ichiro Kurane, Jane Halton, Joachim Klein, John Nkengasong, Peter Piot, Rajeev Venkayya, Trevor Mundel, Richard Hatchett, Helen Rees, Peggy Hamburg, Peter Salama, Tim Evans

Dear Members of the CEPI Board,

Having cooperated extensively in the establishment of CEPI as a novel R&D initiative for public health-driven vaccine development, including as a Board member during its two formative years, we are writing to express our concern and disappointment in CEPI’s revised Equitable Access Policy, which was adopted during your December 2018 Board Meeting. Médecins Sans Frontières (MSF) was heartened by the creation of CEPI to break new ground in public-interest R&D because we believe it is a shared responsibility to ensure scientific and technological progress benefits all people – including the most vulnerable – and because we did not want to ever again be confronted with a terrible and deadly epidemic like the 2014-2016 Ebola outbreak without any tools to effectively respond.

For Reference: CEPI Equitable Access Policy Documents

CEPI’s original ‘Equitable Access’ Policy, 2017.
CEPI’s revised ‘Equitable Access’ Policy for consultation, 2018.

As a medical humanitarian organisation, MSF witnesses the deadly impact of inequitable access to lifesaving drugs and vaccines on a daily basis. For the past 20 years, we have advocated for governments, companies and civil society to assume collective responsibility for ensuring that medical innovation addresses the neglected health needs of people who are most in need. This cannot be achieved through business-as-usual approaches; it requires an innovative approach with a strong public commitment to adopt and enforce transparent, public health-focused rules of engagement with research partners – including the private sector.

CEPI’s revised Equitable Access Policy constitutes an alarming step backwards for the organisation because it no longer guarantees that the vaccines CEPI funds will be made available at an affordable price. It also provides no basis for CEPI to be held accountable to its public and philanthropic investors in its agreements with development partners on the ownership and treatment of intellectual property or the pricing of CEPI-funded vaccines. By replacing the previously detailed equitable access policy with only a broad statement of principle, the revised policy marks a concerning pivot away from CEPI’s early commitments to access, transparency and openness, and to breaking new ground in terms of public responsibility. It betrays the interests of everyone who invested in CEPI because they wanted to change the deadly status quo.

When CEPI was established, its interim Board committed to a strong and visionary access policy to guarantee equitable access to CEPI-funded vaccines, developed with the support of legal experts from WHO, Wellcome Trust and MSF. It contained important safeguards including enforceable commitments on pricing and intellectual property, grounded in transparency and disclosure of information and knowledge. Regrettably, the Board failed to ensure the policy was implemented and used to shape access provisions in the contractual agreements CEPI signed with developers. Instead, supposedly in response to industry actors’ dissatisfaction with the policy, it immediately gave in on its founding principles and decided to revise the access policy.

Over the summer, MSF provided repeated detailed and constructive feedback on the proposed revisions, including a proposal that an Access Advisory Committee of relevant experts be established to provide independent review of the legal agreements concluded with commercial developers from an access perspective. We also suggested ways to integrate access considerations at critical steps along the pathway of vaccines R&D. At the October 2018 Board meeting, we again raised our concerns about the weakening of CEPI’s initial access commitments.

Ultimately, the Board lacked the courage to maintain the critical safeguards built in to the original access policy. We were disappointed to learn that it was replaced by a vague, toothless and weak new policy in December 2018, disregarding our concerns and proposals, while delegating the development of more detailed, but secret, implementation guidance to the Secretariat.

As you meet as a Board later this week in Tokyo, we urge you to reconsider this change in direction, which stands in stark contrast to the original intent of CEPI. We ask that you agree to work quickly to revise your current policy and come to your next Board meeting in June ready to adopt these revisions. The unique thing about CEPI is not the science, but the unprecedented levels of public and philanthropic money provided to make the science possible, in the interest of global public health. CEPI must live up to its promises to break new ground in vaccine R&D and do things differently. At a minimum, this requires the Board to step up now and reintroduce an unapologetic commitment to affordable access and transparency.

Sincerely,

Dr Joanne Liu
MSF International President           

Dr Els Torreele
Executive Director, MSF Access Campaign

::::::

CEPI’s statement in response to MSF’s open letter on equitable access.
Updated March 8
We share MSF’s view on the importance of access to needed vaccines.

The world now has 21 vaccines under development with CEPI funding. We are already engaging with affected countries to ensure that people who need them get them. Our commitment to access is unwavering and our ability to deliver is enhanced by experience.

We’re currently working with affected countries such as Nigeria, DRC, Bangladesh, and India as well as collaborating with public, private, and academic partners to get life-saving vaccines out of the lab and into the clinic so affected populations can benefit.

Achieving our aim requires working with multiple partners and taking multiple approaches to achieve the desired equitable access objectives. As a result of consultation, CEPI’s Equitable Access Policy has evolved from a “rules-based approach” that previously mandated specific access requirements that proved to be a barrier to many potential partners, to a “principles-based approach” that provides a robust foundation for advancing equitable access.

In practice, this means creating legally binding agreements with our partners that embed the principle of equitable access from the outset and which deploy a range of mechanisms for its realisation—whether that be through establishing requirements on access to vaccines (including price) for affected populations or ensuring that data, information, and materials arising from CEPI-funded R&D are rapidly and openly available for further study and research.

Over the past year, we’ve committed to investing up to $350 million in the development of potentially life-saving vaccines. We can now say with assurance that access will be delivered in all circumstances not just those specified in the previous policy.

We appreciate that it’s important this commitment is visible and understood by our partners. So, with the agreements relating to initial calls for proposals now complete, we will publish how access is being achieved for our developing vaccine portfolio by the end of March, 2019.

CEPI’s Equitable Access Policy is available here.

 

FDA Commissioner Scott Gottlieb Announces He Will Resign

Milestones :: Perspectives

FDA Commissioner Scott Gottlieb Announces He Will Resign
March 5, 20194:08 PM ET
Laurel Wamsley

The commissioner of the Food and Drug Administration, Scott Gottlieb, announced Tuesday that he is resigning the position, effective in one month.

Gottlieb won approval from many as an effective advocate for public health. Within the Trump administration, he stood out for his efforts to more tightly regulate several industries; he’s been particularly intent on curbing vaping and making generic drugs more accessible.

Gottlieb is a physician who was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs. He became commissioner in May 2017. The reasons for his resignation are not yet clear, but it appears it was not requested by the White House.

President Trump tweeted his high regard for the commissioner on Tuesday afternoon, writing that he has done “an absolutely terrific job. …. Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!”

Gottlieb tweeted in return that he was “immensely grateful for the opportunity” to lead the agency…

Milestones :: Perspectives DRC – Ebola

Milestones :: Perspectives

DRC – Ebola

 

Ebola Treatment Center in Congo Is Attacked Again; 1 Dead
March 9, 2019  By The Associated Press

KINSHASA, Congo — Heavily armed assailants again attacked an Ebola treatment center in the heart of eastern Congo’s deadly outbreak on Saturday, with one police officer killed and health workers injured, authorities said, while frightened patients waited in isolation rooms for the gunfire to end.

The early-morning attack in Butembo came less than a week after the treatment center reopened following an attack last month, which forced Doctors Without Borders to suspend operations in the city amid warnings that ending this outbreak is impossible if health workers aren’t protected.

Dozens of armed groups are active in mineral-rich eastern Congo, though some have allowed health workers access to administer Ebola vaccines and track contacts of infected people after delicate negotiations.

Security forces on Saturday repelled the attackers, one of whom was wounded, Butembo Mayor Sylvain Kanyamanda said. Congo’s health ministry in a statement said forces had surrounded the center after being tipped to a possible assault, “saving many lives.”

The attack occurred hours before the World Health Organization director-general and the Centers for Disease Control and Prevention director visited the center, which remained open. WHO chief Tedros Adhanom Ghebreyesus encouraged workers to continue their fight against the second-deadliest Ebola outbreak in history, which is spreading in a region compared to a war zone… 

::::::

WHO Director-General reiterates commitment to Ebola response despite another attack
9 March 2019   Statement
Butembo, Democratic Republic of the Congo

WHO Director-General, Dr Tedros Adhanom Ghebreyesus today visited an Ebola treatment centre in Butembo, in the Democratic Republic of the Congo, that was attacked by armed groups last week and again earlier today. He spoke with personnel in the centre and thanked them for their dedication.

The visit came as he concluded a three-day mission to the country, along with senior US officials and other WHO leadership. They met with the President, government officials, partner organizations and local responders involved in the outbreak response. He spoke to a group of partners, officials and staff in Butembo on Saturday morning.

“It breaks my heart to think of the health workers injured and police officer who died in today’s attack, as we continue to mourn those who died in previous attacks, while defending the right to health,” said Dr Tedros. “But we have no choice except to continue serving the people here, who are among the most vulnerable in the world.”

“These are not attacks BY the community, they are attacks ON the community. There are elements who are exploiting the desperation of the situation for their own purposes. The people of Katwa and Butembo, as in the other communities affected by Ebola, want and deserve a place to receive care and a chance of survival. They do not deserve to suffer in their homes while infecting their loved ones, they do not deserve to suffer in inadequately resourced health centers while infecting health workers,” he added.

WHO has requested and received further support from UN and local police forces to protect the treatment centres. To conquer Ebola, we must strike a delicate balance between providing accessible care, maintaining the neutrality of the response, and protecting patients and staff from attacks by armed groups. These are the dilemmas we face in conflict zones around the world.  We are committed to ending the outbreak, and we are committed to improving the health of the people of DRC,” he concluded.

 

::::::

 

31: Situation report on the Ebola outbreak in North Kivu  3 March 2019
[Excerpt]
Implementation of ring vaccination protocol

A total 585 community rings have been defined and vaccinated, including two targeted geographic zones. In total, 85,341 contacts and contacts of contacts have been vaccinated (including health workers and front-line workers). Of those who consented and were vaccinated, 21,511 are contacts and 63,615 are contacts of contacts. The total consented and vaccinated includes 26 601 health workers and front-line workers, while 21,135 are children between 1-17 years. In addition, vaccination of health workers and front-line workers is ongoing in the neighbouring areas where there is a possibility of spread. In Goma, 3896 health workers and front-line workers have been vaccinated. In Uganda, 4852 health workers and front-line workers have been vaccinated. In South Sudan 1138 health workers and front-line workers have been vaccinated. Vaccination is planned to start in a week’s time in Rwanda and preparations are underway in Burundi.

Risk communication, social mobilization and community engagement

Since the recent attack on the two ETCs in Katwa and Butembo, WHO, UNICEF and partners have been supporting the MoH in setting up platforms to directly dialogue with local politicians, key community leaders and influencers, and pressure groups at health area levels in Katwa, Vihovi and Kyondo health zones to better understand their needs and come up with a common understanding and joint action towards stopping the Ebola outbreak.

Risk communication and social anthropologist teams have strengthened community engagement activities in Katwa. Risk communication and community engagement orientation sessions were organized for different pillars of the response to enhance capacity of RECOs and other Ebola response personnel to address community concerns.

Risk communication and community engagement activities in other health zones, including Mangina, Bunia, Beni, Oicha and Komanda continues, with a focus on communicating about the current situation of the Ebola outbreak and the response.

In Oicha’s Tenambo health area, women eligible for the Ebola vaccine (as contacts or contacts of contacts) were sensitized on the importance of vaccination. EVD awareness activities were carried out for women in the market in Bwanasura, and for teachers from the Vutsundo health area. A visit to Butembo ETC was organised for some community representatives to show them how patients are being cared for in the treatment centre…

 

DONS – Ebola virus disease – Democratic Republic of the Congo

7 March 2019
[Excerpt]
…Following the attacks on two ETCs in Katwa and Butembo, patients were temporarily transferred to the Katwa Transit Centre. On 2 March, the Butembo ETC was rehabilitated and resumed treatment of EVD patients. Response teams are progressively resuming activities in all affected areas with the exception of two health areas where security and community resistance remain a challenge…

::::::

Ebola response failing to gain the upper hand on the epidemic – MSF
Democratic Republic of Congo
Press Release 7 Mar 2019
:: Despite a rapid and large outbreak response with new vaccines and treatments, the signs are that Ebola is not under control
:: Since the beginning of the year, more than 40 per cent of new Ebola cases are people who died of Ebola in the communities
:: Patients and communities must be treated as partners in the response; we must listen to their needs not preach to or coerce them
Seven months into the largest-ever Ebola outbreak in the Democratic Republic of the Congo (DRC), the Ebola response is failing to bring the epidemic under control in a climate of deepening community mistrust, Médecins Sans Frontières (MSF) said at a press conference in Geneva today.

Since the beginning of the year, more than 40 per cent of new cases are people who died of Ebola in the communities. At the epicentre of the epidemic, in Katwa and Butembo in North Kivu province, 43 per cent of patients in the last three weeks were still being infected without known links to other cases.

“We have a striking contradiction: on the one hand a rapid and large outbreak response with new medical tools such as vaccines and treatments that show promising outcomes when people come early – and on the other hand, people with Ebola are dying in their communities, and do not trust the Ebola response enough to come forward,” said International President of MSF, Dr Joanne Liu.

Last week, MSF suspended our Ebola activities in Katwa and Butembo, in North Kivu province, after successive attacks on the two treatment centres. While MSF does not know the motives or identities of the attackers, these incidents follow an escalation of tensions around the Ebola response. Dozens of security incidents occurred against the response as a whole in the month of February alone. While the causes of these acts are not all the same, it is clear that various political, social and economic grievances are increasingly crystallising around the response.

A range of issues have led to these tensions: from the massive deployment of financial resources focusing only on Ebola, in a neglected region suffering from conflict, violence and long-standing health needs; to elections being officially postponed due to the Ebola outbreak, exacerbating suspicions that Ebola is a political ploy.

The use of police and armed forces to compel people to comply with health measures against Ebola is leading to further alienation of the community and is counterproductive to controlling the epidemic. Using coercion for activities such as safe burials, tracking of contacts and admission into treatment centres discourages people from coming forward and pushes them into hiding.

The Ebola response must take a new turn. Choices must be given back to patients and their families on how to manage the disease. Vaccination for Ebola must reach more people, and more vaccines are needed for this. Other dire health needs of communities should be addressed. And coercion must not be used as a tactic to track and treat patients, enforce safe burials or decontaminate homes.

“Ebola is a brutal disease, bringing fear, and isolation to patients, families and health care providers,” said Dr Joanne Liu. “The Ebola response needs to become patient and community centred. Patients must be treated as patients, and not as some kind of biothreat.”

Seven months since the beginning of the current Ebola outbreak in the provinces of North Kivu and Ituri, there have been 907 cases of Ebola cases (841 confirmed and 66 probable) and 569 people have died. [source: World Health Organization (WHO) report week 9]

 

Further to the suspension of its activities in Katwa and Butembo, MSF has maintained its Ebola-related activities in the North Kivu towns of Kayna and Lubéru, as well as its management of two Ebola transit  facilities in Ituri province, in the towns of Bwanasura and Bunia. In the city of Goma, MSF has been supporting emergency preparedness by reinforcing the surveillance system and ensuring there is adequate capacity to manage suspected cases.

 

It has almost been six years, since 11 July 2013, that three MSF staff remain missing after being abducted in Kamango, Nord Kivu, where they were carrying out a health assessment. MSF continues to search for them.

:::::: 

Wellcome pledges new funds to tackle Ebola outbreak – but more is needed to prevent catastrophe

Wellcome is making £2 million available to the WHO and government of DRC, to support vaccine research as part of the emergency response to the Ebola outbreak.

News | 6 March 2019

The pledge comes after the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, called on donors to continue funding the response to the Ebola outbreak. There is a risk the response will slow down if current actions are not sustained and intensified.

Since the outbreak began in August 2018, there have been over 800 Ebola virus cases in the area, including 563 deaths.

Jeremy Farrar, Director of Wellcome, said: “The Ebola virus has taken hold in an incredibly challenging region and recent attacks on treatment centres show that the security situation is a very real concern which will impact on the epidemic. The outbreak is in danger of spreading within the DRC, and if the international community doesn’t step up their support, there is real risk that this outbreak will get out of control, cross borders and take off as it did in the West African epidemic where over 11,000 people died.”

“To prevent catastrophe, the international response must be significantly increased to support the incredible work led by DRC. The DRC, WHO and partner’s public health teams have provided an amazing response, but the situation is fragile and they need global support to ensure this outbreak is contained effectively. Wellcome is committed to helping the world tackle the Ebola threat and we have made £2 million available immediately to support the response. Further funds will be needed, and we are working with our global partners to address these needs.”

Wellcome’s £2m emergency funding is provided through the Joint Initiative on Epidemic Preparedness, a partnership with the UK Department for International Development (DFID) that is part of our work on vaccines

 

::::::
::::::

 

Emergencies

Emergencies
 
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 6 March 2019
:: On 26-27 February 2019, the Global Commission for Certification of the Eradication met at the World Health Organization in Geneva to continue its work on global certification criteria for wild poliovirus eradication and containment.  The GCC reviewed all the latest global epidemiology and examined remaining challenges in the interruption of wild polio virus. Read more here.
:: Featured on polioeradication.org: Coffee with Polio Experts— Dr Nicksy Gumede-Moeletsi, senior virologist at WHO’s Regional Office for Africa, talks about how genetic analysis of isolated polioviruses is helping strategically drive eradication efforts in Africa.
 
 
Summary of new viruses this week:
:: Pakistan – two WPV1-positive environmental samples;
:: Nigeria — one circulating vaccine-derived poliovirus type 2 (cVDPV2) case.
 
 
::::::
 
 
GCC intensifies work on global certification criteria
Global Commission for Certification of Poliomyelitis Eradication (GCC) meet in Geneva to intensify its work on global certification criteria
On 26-27 February 2019, the Global Commission for Certification of Poliomyelitis Eradication (GCC) met at the World Health Organization (WHO) headquarters in Geneva, Switzerland, to continue its intensified work on global certification criteria for poliomyelitis eradication and poliovirus containment.  The work of the GCC is critical to verifying the achievement of a world free of all polioviruses
 
 
The GCC reviewed the latest global epidemiology of all poliovirus transmission, examined remaining challenges such as subnational surveillance and immunity gaps, and evaluated current containment status.

The GCC expressed its concerns over the lack of progress in the interruption of transmission of wild poliovirus type 1 (WPV1) in Pakistan and Afghanistan and the spread of vaccine-derived polioviruses (VDPVs). As expressed in a recently-published letter from the four Chairs of the GPEI’s main global advisory bodies, it is essential that improvement is achieved in both routine immunization services and supplementary immunization activity (SIA) quality. Nevertheless, the GCC is continuing to accelerate its work, including taking into consideration circulating vaccine-derived polioviruses (cVDPVs), which continue to take on added significance as the time extends since the discontinuation of type 2 poliovirus in oral polio vaccine (OPV) with consequent loss of type 2 polio immunity. The GCC is also occupied with the urgent and increasing need for effective containment of polioviruses in laboratories and vaccine manufacturing facilities.

Noting that wild poliovirus type 3 (WPV3) has not been isolated anywhere since November 2012, the GCC re-affirmed its decision to undertake sequential certification of WPV eradication, meaning that WPV3 will be certified as eradicated prior to WPV1.  The GCC has requested that the Director-General of WHO ask the Regional Directors of Africa and the Eastern Mediterranean respectively to confirm from their Member States that the last WPV3s in both Regions were identified more than six years ago. The GCC will review these data in conjunction with the final reports from the four Regions that have already been certified. This will permit the GCC to certify the eradication of WPV3.

The GCC noted progress in identifying the interruption of WPV1 transmission in the African Region, which will be eligible for regional certification when the African Regional Certification Commission is convinced of the evidence of absence of wild polioviruses that meets surveillance standards.

The outcomes and recommendations of the GCC will be presented to the WHO Director-General, and if accepted, incorporated into the Global Polio Eradication Initiative Strategic Plan 2019-2023.  The full report from the GCC’s meeting will be made available at www.polioeradication.org.

 

::::::
::::::

 

Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies  [to 9 Mar 2019]
Democratic Republic of the Congo
:: 31: Situation report on the Ebola outbreak in North Kivu  3 March 2019
:: DONS – Ebola virus disease – Democratic Republic of the Congo   7 March 2019

Syrian Arab Republic
:: Unexploded mines pose daily risk for people in northern Syria   6 March 2019

Bangladesh – Rohingya crisis
:: Bi‐weekly Situation Report 4 – 04 March 2019

 

Myanmar – No new digest announcements identified  
Nigeria – No new digest announcements identified  
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified  
Yemen – No new digest announcements identified  

::::::

 

WHO Grade 2 Emergencies  [to 9 Mar 2019]
Libya
:: WHO responds to critical health needs in southern Libya
6 March 2019 – In response to increasing violence in Sabha City, southern Libya, the World Health Organization (WHO) has delivered trauma medicines sufficient for more than 400 patients requiring trauma care to Sabha Medical Centre, Murzuq General hospital and Ghodwa field hospital. WHO has also delivered 6 incubators and 2 ventilators to the neonatal intensive care unit of Sabha Medical Centre, and pre-positioned additional trauma medicines at the Medical Supply Office in Sabha to be delivered to health facilities as needed.

Clashes between armed groups in Sabha and Murzuq in February resulted in increasing numbers of injured patients, overwhelming health facilities already facing shortages of specialists and medical supplies. The total number of casualties is 250, which includes 44 dead and 206 wounded…

Brazil (in Portugese) – No new digest announcements identified
Cameroon  – No new digest announcements identified
Central African Republic  – No new digest announcements identified
Ethiopia – No new digest announcements identified
Hurricane Irma and Maria in the Caribbean – No new digest announcements identified
Iraq – No new digest announcements identified  
MERS-CoV – No new digest announcements identified
Niger – No new digest announcements identified
occupied Palestinian territory  – No new digest announcements identified  
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new digest announcements identified
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

::::::

 

WHO Grade 1 Emergencies  [to 9 Mar 2019]
Afghanistan
Chad
Indonesia – Sulawesi earthquake 2018
Kenya
Lao People’s Democratic Republic
Mali
Namibia – viral hepatitis
Peru
Philippines – Tyhpoon Mangkhut
Tanzania

::::::

WHO AFRO – Outbreaks and Emergencies Bulletin – Week 09/2019
Week 09: 25 February – 03 March 2019
The WHO Health Emergencies Programme is currently monitoring 59 events in the region. This week’s edition covers key new and ongoing events, including:
:: Ebola virus disease in the Democratic Republic of the Congo
:: Measles in Madagascar
:: Lassa fever in Nigeria
:: Humanitarian crisis in Nigeria
:: Humanitarian crisis in South Sudan 

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic   – No new digest announcements identified
Yemen – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia 
:: Ethiopia Humanitarian Bulletin Issue #4 | 17 February – 03 March 2019

HIGHLIGHTS
The Government of Ethiopia and humanitarian partners will formally launch the 2019 Ethiopia Humanitarian Response Plan (HRP) on 7 March.
Some 90,000 displaced people in Amhara region need urgent assistance.
Improved security along the OromiaSomali border is enabling humanitarian partners to move relief commodities to Dawa zone after more than a year.

Somalia 
:: Humanitarian Bulletin Somalia, 1 February – 5 March 2019

Highlights
– Dry conditions worsen across Somalia.
– Protecting livestock to save livelihoods.
– Access constraints continue.
– Redoubling efforts to End Polio Outbreaks.
– Sustained response through pooled funds.

::::::
::::::

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 9 Mar 2019]
http://www.who.int/ebola/en/
:: 31: Situation report on the Ebola outbreak in North Kivu  3 March 2019
:: DONS – Ebola virus disease – Democratic Republic of the Congo   7 March 2019
 
 
MERS-CoV [to 9 Mar 2019]
http://who.int/emergencies/mers-cov/en/
– No new digest announcements identified.
 
 
Yellow Fever  [to 9 Mar 2019]
http://www.who.int/csr/disease/yellowfev/en/
– No new digest announcements identified.
 
 
Zika virus  [to 9 Mar 2019]
http://www.who.int/csr/disease/zika/en/
– No new digest announcements identified.

 

WHO & Regional Offices [to 9 Mar 2019]

WHO & Regional Offices [to 9 Mar 2019]
9 March 2019   Statement
WHO Director-General reiterates commitment to Ebola response despite another attack
Butembo, Democratic Republic
[See DRC Ebola above for detail]

:::::: 
Weekly Epidemiological Record, 8 March 2019, vol. 94, 10 (pp. 117–128)
:: Paraguay and Uzbekistan certified as malaria-free
:: Update on vaccine-derived poliovirus outbreaks – Democratic Republic of the Congo, Horn of Africa, 2017–2018

::::::
 
Calls for consultants / proposals
6 March 2019
Rubella Vaccination Systematic Review pdf, 270kb
Deadline for applications: 27 March 2019
 
::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Bilateral ties between WHO African Regional Secretariat and Republic of Congo gets a significant boost  08 March 2019

:: Dynamic staff and sparkling maternity complex deliver improved maternal health in South Sudan  07 March 2019
:: Mass measles vaccination campaign underway in response to outbreak in Mayom, South Sudan  06 March 2019
:: The Republic of Congo starts vaccinating 2.2 million children against Measles and Rubella
05 March 2019
: Africa’s first-ever mass typhoid fever vaccination campaign ends in Zimbabwe  04 March 2019
::  WHO remains mobilized against Lassa fever cases as number of cases go down in affected areas  04 March 2019

WHO Region of the Americas PAHO
:: International Women’s Day: Access to health for migrant women remains a challenge in the Americas (03/08/2019)
:: Half of all deaths of young people in the Americas can be prevented (03/05/2019)
 
 
WHO South-East Asia Region SEARO
– No new digest announcements identified.
 
 
WHO European Region EURO
:: National policy experts call for bold action for healthy ageing in the Region 08-03-2019
:: Zsuzsanna Jakab appointed WHO Deputy Director-General 07-03-2019
:: WHO studies reveal Kazakhstan has among the highest levels of salt intake globally 07-03-2019
:: International Women’s Day: women in health innovating for change 07-03-2019
:: Romanian EU Presidency aims to strengthen Europe’s One Health approach to fighting antimicrobial resistance 06-03-2019
 
 
WHO Eastern Mediterranean Region EMRO
:: Women on the frontlines of polio eradication  7 March 2019
:: Unexploded mines pose daily risk for people in northern Syria  6 March 2019
 
 
WHO Western Pacific Region
– No new digest announcements identified.

CDC/ACIP [to 9 Mar 2019]

CDC/ACIP [to 9 Mar 2019]

http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for March 8, 2019
Progress toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017
Hepatitis B vaccination significantly reduced hepatitis B infections among children in the Western Pacific Region, from 8 percent (considered a high endemicity rate) to less than 1 percent (considered a low endemicity rate). Hepatitis B (HepB), a vaccine preventable disease, is a major cause of liver cancer. After all countries/areas in the Western Pacific Region (WPR) introduced the HepB vaccine into childhood immunization schedules, childhood infections dropped from a high of more than 8 percent in 1990 to less than 1 percent by 2017. These remarkable immunization achievements prevented more than 37 million chronic infections and 7 million HepB-related deaths. Further HepB control includes improving HepB birth-dose coverage through increased health facility births, antenatal training, and outside-the-cold-chain use. In addition to maintaining high vaccine coverage, additional interventions like routine antenatal testing, administration of hepatitis B immunoglobulin to exposed newborns, and antiviral treatment of mothers would be needed to achieve elimination of mother-to-child transmission of HepB by 2030.

Notes from the Field:
Notes from the Field: Measles Outbreak in an Era of Stricter Immunization Requirements — California, March 2018

Africa CDC   [to 9 Mar 2019]

Africa CDC   [to 9 Mar 2019]

https://au.int/en/africacdc
Event
March 13, 2019 to March 15, 2019
International Conference on (RE-) Emerging Infectious Diseases (ICREID)
WHO: Representatives of AU Member States, WHO, World Bank, US CDC, China CDC, EU CDC, London School of Hygiene and Tropical Medicine, Harvard School of Public Health, and healthcare professionals, researchers, public health experts and policymakers involved in treatment, research, discovery and development of drugs and vaccines in the field of re-emerging infectious diseases from around the world (over 300 participants expected).
WHEN: 13-15 March 2019
TIME: 9.00 am to 5.30 pm daily
WHERE: African Union Commission, Addis Ababa
BACKGROUND INFORMATION
Hosted by Africa CDC, ICREID is a global platform that brings together experts from around the world to discuss emerging and re-emerging diseases in an interactive conference setting. It is the first of its kind to be held in Africa and will feature presentations by distinguished healthcare professionals, researchers, public health experts and policymakers involved in treatment, research, discovery and development of drugs and vaccines in the field of re-emerging infectious diseases around the world. It is a highly scientific and educative abstract-driven conference consisting of keynote speeches, state-of-the-art lectures, oral and poster abstract presentations, roundtable discussions, debates, and in-depth discussions to exchange knowledge on the latest clinical developments and updates on ongoing and new trials on various emerging and re-emerging diseases. The conference will provide a platform for new data to be translated into treatment and intervention guidelines and will create a unique opportunity for community-building and networking in Africa.

 

Announcements

Announcements

Paul G. Allen Frontiers Group [to 9 Mar 2019]
https://www.alleninstitute.org/news-press/
No new digest content identified.

BMGF – Gates Foundation [to 9 Mar 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 9 Mar 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 9 Mar 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
03.04.2019
CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
ContraFect’s new class of phage-encoded lytic agents called ‘amurins’ aims to treat the deadliest drug-resistant Gram-negative pathogens

CEPI – Coalition for Epidemic Preparedness Innovations  [to 9 Mar 2019]
http://cepi.net/
07 Mar 2019
Nipah – The Next Global Pandemic?
Last year, Stanford epidemiologist and Nipah expert Stephen Luby, a scientist who forms part of the team working on our University of Tokyo partnership to develop a Nipah vaccine, spoke about the risks posed by the 2018 Nipah virus outbreak and potential interventions to halt its spread.
[See Milestones above for an exchange of letters between MSF and CEPI.
EDCTP    [to 9 Mar 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

Emory Vaccine Center    [to 9 Mar 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

European Medicines Agency  [to 9 Mar 2019]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 

European Vaccine Initiative  [to 9 Mar 2019]
http://www.euvaccine.eu/news-events
Latest news
Launch of SENET – the Sino-European Health NETworking Hub
05 March 2019
EVI supports new EC-funded project that aims to strengthen international research and innovation cooperation between China and the EU

 
 
FDA [to 9 Mar 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
[See Milestones above for coverage of Commissioner Scott Gottlieb’s announced resignation.]

Fondation Merieux [to 9 Mar 2019]
http://www.fondation-merieux.org/
No new digest content identified.

Gavi [to 9 Mar 2019]
https://www.gavi.org/
Latest News
Gavi signs new cooperation agreement with Japan International Cooperation Agency
05 March 2019
Geneva, 5 March 2019 – Gavi, the Vaccine Alliance and the Japan International Cooperation Agency (JICA) will work together to boost vaccine coverage and improve health systems in the world’s poorest countries following the signing of a new Memorandum of Cooperation…
“Japan has been a key Gavi supporter since 2011, helping us to vaccinate millions of children against some of the world’s deadliest diseases,” said Dr Berkley. “I’m delighted to sign this new agreement with Dr Toda, which will ensure we continue to work together to improve the health of children worldwide for years to come.”
The Memorandum of Cooperation commits both Gavi and JICA to collaborate to enhance information sharing and improve the use of innovation in areas including modernisation of the cold chain, digital identification and the digitalisation of maternal and child health and immunisation data.
The two organisations will also promote the dissemination of integrated records, such as a maternal and child health handbook, and explore ways to promote the sustainability of immunisation programmes through technical cooperation and the use of innovative financing instruments.
The Japan International Cooperation Agency (JICA) coordinates Japan’s official development assistance (ODA).

GHIT Fund [to 9 Mar 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 9 Mar 2019]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.

Hilleman Laboratories [to 9 Mar 2019]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 9 Mar 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI [to 9 Mar 2019]
https://www.iavi.org/newsroom
No new digest content identified.

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

IVAC [to 9 Mar 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.

IVI   [to 9 Mar 2019]
http://www.ivi.int/
IVI News & Announcements
IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa
[Undated]
SEOUL, Korea — The International Vaccine Institute (IVI) has been awarded a $3,238,974 grant from the Bill & Melinda Gates Foundation to provide technical assistance support for studies to measure the effectiveness of typhoid conjugate vaccine (TCV) in West Africa.

This grant comes after a consortium, led by the University of Cambridge, Department of Medicine (UCAM), was awarded a €13 million grant from the European and Developing Countries Clinical Trials Partnership (EDCTP). This EDCTP “THECA” grant will fund the assessment of the effectiveness of a novel TCV through two clinical studies: a cluster-randomized trial in Ghana and a mass vaccination campaign with a nested case-control effectiveness component in the Democratic Republic of the Congo (DRC).

IVI is an integral part of the consortium with partners from Ghana, the DRC, Belgium, Bangladesh, Madagascar, Burkina Faso, the United Kingdom, and the United States. The technical support to THECA, funded by this grant from the Bill & Melinda Gates Foundation, will continue through May 2023.

“Typhoid is a poverty-associated infectious disease. It strikes the impoverished and frequently occurs in low-income settings where there is a lack of access to clean water and where sanitation and hygiene are poor. Infants and young children are at higher risk,” said Mr. Justin Im, Associate Research Scientist in the Epidemiology and Outcomes Unit. “IVI is proud to be a member of the consortium that will evaluate the effectiveness of the novel TCV.”…
 
 
JEE Alliance  [to 9 Mar 2019]
https://www.jeealliance.org/
Selected News and Events
Mali – A Multi-sectoral and Multi-stakeholder Cooperation Success Story
8.2.2019
Disease outbreaks continue to occur in Mali and the ongoing security crisis highlights the importance of a comprehensive national framework for health security. Recognizing the need for cooperation…
 
 MSF/Médecins Sans Frontières  [to 9 Mar 2019]
http://www.msf.org/
Selected News; Project Updates, Reports [as presented on website]
Democratic Republic of Congo
Ebola response failing to gain the upper hand on the epidemic
Press Release 7 Mar 2019
[See DRC Ebola above for detail]
 
 
Women’s health
Unsafe abortion: a forgotten emergency
Project Update 4 Mar 2019
 
 
NIH  [to 9 Mar 2019]
http://www.nih.gov/news-events/news-releases

News Releases
Researchers report high rate of viral suppression among people new to HIV care
March 7, 2019 — NIH-funded study reflects advances in HIV care, but gaps remain.

Tuberculosis diagnosis in people with HIV increases risk of death within 10 years
March 6, 2019 — NIH-supported analysis identified elevated mortality in large Latin American cohort.

Study finds Ebola survivors in Liberia face ongoing health issues
March 6, 2019 — Report compares health outcomes in survivors and contacts during their first year of study participation.

HIV prevention study finds universal “test and treat” approach can reduce new infections
March 5, 2019 — NIH-sponsored trial suggests home-based HIV testing and referral to care works at population level.
 
 
PATH  [to 9 Mar 2019]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 9 Mar 2019]

http://www.sabin.org/updates/pressreleases

Tuesday, March 5, 2019

Sabin Statement on Senate HELP Committee Hearing on What is Driving Preventable Disease Outbreaks

WASHINGTON, D.C. – Today, the Senate Health, Education, Labor, and Pensions (HELP) Committee conducted a hearing on rising rates of vaccine hesitancy causing preventable disease outbreaks across the country – such as the ongoing outbreaks in Washington, Illinois and New York.

Sabin applauds Senate HELP Committee Chair Lamar Alexander (R-TN) and Ranking Member Patty Murray (D-WA) for providing a forum for public health experts to share their expertise and stories on the importance of vaccination to public health.

“The science is clear – vaccines are proven to work. Their introduction is one of the greatest public health innovations in the 20th century, though millions around the globe are still impacted by vaccine-preventable diseases. We commend the Senate HELP Committee for raising this issue to a national platform and addressing the surge of false information found on social media,” said Bruce Gellin, M.D., M.P.H., Sabin’s president of Global Immunization.
 
 
UNAIDS [to 9 Mar 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
8 March 2019
Africa — Achieving health coverage without compromising on quality
 
 
8 March 2019
People living with HIV face major challenges in Zimbabwe
 
 
7 March 2019
Turning words into action for gender equality
 
 
UNICEF  [to 9 Mar 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
No new digest content identified.
 
 
Vaccine Confidence Project  [to 9 Mar 2019]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 9 Mar 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 9 Mar 2019]
https://wellcome.ac.uk/news
News | 6 March 2019
Wellcome pledges new funds to tackle Ebola outbreak – but more is needed to prevent catastrophe
Wellcome is making £2 million available to the WHO and government of DRC, to support vaccine research as part of the emergency response to the Ebola outbreak.
[See DRC-Ebola above for more detail]
 
 
The Wistar Institute   [to 9 Mar 2019]
https://www.wistar.org/news/press-releases
Press Release  Mar. 6, 2019
New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers
First-in-class pharmacological inhibitors of the EBNA1 viral protein are effective at inhibiting tumor growth in preclinical models.
 
 
World Organisation for Animal Health (OIE) [to 9 Mar 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

::::::

BIO [to 9 Mar 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 9 Mar 2019]
http://www.dcvmn.org/
No new digest content identified.

IFPMA [to 9 Mar 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

PhRMA [to 9 Mar 2019]
http://www.phrma.org/press-room
No new digest content identified.

Journal Watch

 

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Further Evidence of MMR Vaccine Safety: Scientific and Communications Considerations

Annals of Internal Medicine
5 March 2019 Vol: 170, Issue 5
http://annals.org/aim/issue

Editorials
Further Evidence of MMR Vaccine Safety: Scientific and Communications Considerations
Saad B. Omer, MBBS, MD, PhD; Inci Yildirim, MD, PhD, MSc
It has been 20 years since, in a subsequently retracted study, Wakefield and colleagues (1) reported on 12 children with developmental delay, 8 of whom were diagnosed with autism within 4 weeks of receiving the measles, mumps, rubella (MMR) vaccine. Despite substantial limitations, the study received wide publicity, and the claims published in the article contributed to damaging confidence in the safety of the MMR vaccine, leading to a sharp drop in vaccination rates in the United Kingdom and, possibly, in other countries.

Since the publication of the initial report by Wakefield and colleagues, and despite many subsequent studies not finding an association between MMR vaccine and autism, public concerns regarding a potential link between MMR vaccine and the development of autism have persisted. In one of the largest studies to date, Madsen and colleagues (2) conducted a retrospective analysis of 537 303 children born in Denmark between 1991 and 1998, representing 2 129 864 person-years, to assess a potential link between autism and receipt of MMR vaccine. They concluded that MMR vaccine was not associated with development of autism and that the risk for autism in the group of vaccinated children was the same as that in unvaccinated children. This study also demonstrated that there was no association between the child’s age at the time of vaccination or the time since vaccination and the development of autism. Moreover, in a recent meta-analysis involving 5 large cohort studies (N = 1 256 407 children) and 5 case–control studies (N = 9920 children), there was no relationship between MMR vaccination and autism (odds ratio, 0.84 [95% CI, 0.70 to 1.01]) (3).

In this issue, Hviid and colleagues (4) report another nationwide cohort study from Denmark. They used a Cox proportional hazards regression model to evaluate whether receipt of MMR vaccine increased the risk for autism in children born between 1999 and 2010. They captured 5 025 754 person-years of follow-up and estimated an adjusted hazard ratio of 0.93 (95% CI, 0.85 to 1.02) among children who received MMR vaccine compared with those who did not.

This is one of the largest studies published on MMR vaccine and autism. Hviid and colleagues included 6517 children with a diagnosis of autism in their cohort by using the Danish Psychiatric Central register. This allowed the investigators to define risk for autism in subgroups of children who may be more susceptible to developing this condition, such as those with a sibling history of autism. One critique of previous studies is a supposedly inadequate focus on subgroups of children considered by some, not always on the basis of evidence, to be at a high risk for autism. Therefore, it is important to note that Hviid and colleagues observed no increased risk for autism in several subgroups: children with a sibling history of autism, children who received other childhood vaccines, or during certain time periods after receipt of vaccine.

In the context of this new study, and given that mainstream studies have consistently pointed toward a lack of association between MMR vaccine and autism, a couple of questions arise. First, is there sufficient uncertainty to warrant additional studies? Second, what impact will the accumulating evidence refuting an MMR–autism association have on the public perception of vaccine safety?

In an ideal world, vaccine safety research would be conducted only to evaluate scientifically grounded hypotheses, not in response to the conspiracy du jour. In reality, hypotheses propagated by vaccine skeptics can affect public confidence in vaccines. Therefore, in some cases, investigators continue to add to the evidence base on safety, even after clinical equipoise has been largely resolved. This may be justified if the cost, including the opportunity cost, of these studies is not too high. For example, analyzing an existing administrative or surveillance database—as was the case in Hviid and colleagues’ study—is likely to require substantially fewer resources than a prospective study. Irrespective of the absolute costs, the opportunity cost of this research should be kept in mind: For example, continuing to evaluate the MMR-autism hypothesis might come at the expense of not pursuing some of the more promising leads.

Even in the face of substantial and increasing evidence against an MMR–autism association, the discussion around the potential link has contributed to vaccine hesitancy. As a result of a successful immunization program, measles was declared eliminated in the United States in 2000 (5). However, misinformation and the reluctance of many parents to vaccinate their children contributed to the 2015 measles outbreak in Disneyland in California (6) and the 2017 outbreak in Minnesota (7). Five outbreaks have already been reported only in 2019, in which the majority of cases were unvaccinated (8).

Therefore, generating evidence on MMR vaccine safety may be useful but is certainly not sufficient. It has been said that we now live in a “fact-resistant” world where data have limited persuasive value. So how do physicians and public health officials debunk the MMR–autism myth?

An approach similar to that proposed by Cook and Lewandowsky (9) may be useful in addressing the misperceptions regarding vaccines and autism. First, any myth should be clearly labeled as such. For example, there is evidence that a misleading headline can induce a reader to remember the inaccurate information while discounting the correct information presented subsequently. Second, while confronting the erroneous information, the focus should be on a few key facts; it is not essential to rebut every piece of misinformation. Finally, an alternative explanation of the perceived phenomenon should be provided. Otherwise, the individual can revert to their original erroneous belief. A recent book provides talking points to clinicians for addressing common vaccine safety questions, including questions around vaccines and autism, based on the latest vaccine safety literature and these and other evidence-based communications approaches (10).

Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study [Free]

Annals of Internal Medicine
5 March 2019 Vol: 170, Issue 5
http://annals.org/aim/issue

Original Research |5 March 2019
Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study [Free]
Anders Hviid, DrMedSci; Jørgen Vinsløv Hansen, PhD; Morten Frisch, DrMedSci; Mads Melbye, DrMedSci
Abstract
Background:
The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause concern and challenge vaccine uptake.
Objective:
To evaluate whether the MMR vaccine increases the risk for autism in children, subgroups of children, or time periods after vaccination.
Design:
Nationwide cohort study.
Setting:
Denmark.
Participants:
657,461 children born in Denmark from 1999 through 31 December 2010, with follow-up from 1 year of age and through 31 August 2013.
Measurements:
Danish population registries were used to link information on MMR vaccination, autism diagnoses, other childhood vaccines, sibling history of autism, and autism risk factors to children in the cohort. Survival analysis of the time to autism diagnosis with Cox proportional hazards regression was used to estimate hazard ratios of autism according to MMR vaccination status, with adjustment for age, birth year, sex, other childhood vaccines, sibling history of autism, and autism risk factors (based on a disease risk score).
Results:
During 5,025,754 person-years of follow-up, 6517 children were diagnosed with autism (incidence rate, 129.7 per 100.000 person-years). Comparing MMR-vaccinated with MMR-unvaccinated children yielded a fully adjusted autism hazard ratio of 0.93 (95% CI, 0.85 to 1.02). Similarly, no increased risk for autism after MMR vaccination was consistently observed in subgroups of children defined according to sibling history of autism, autism risk factors (based on a disease risk score) or other childhood vaccinations, or during specified time periods after vaccination.
Limitation:
No individual medical charts were reviewed.
Conclusion:
The study strongly supports that MMR vaccination does not increase the risk for autism, does not trigger autism in susceptible children, and is not associated with clustering of autism cases after vaccination. It adds to previous studies through significant additional statistical power and by addressing hypotheses of susceptible subgroups and clustering of cases.
Primary Funding Source:
Novo Nordisk Foundation and Danish Ministry of Health.
 

Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 9 Mar 2019)

Research article
Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage
There is great interest in the use of reduced dosing schedules for pneumococcal conjugate vaccines, a strategy premised on maintaining an acceptable level of protection against disease and carriage of the orga…
Authors: Alan Yang, Francisco Cai and Marc Lipsitch
Citation: BMC Infectious Diseases 2019 19:227
Published on: 5 March 2019